OBIO
$4.61
Orchestra BioMed Holdings, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, a...
Recent News
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +168.87% and +3,813.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +2,100.00% and +1.61%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17%
Key Insights Orchestra BioMed Holdings' significant retail investors ownership suggests that the key decisions are...
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs
Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) is one of the best biotech penny stocks to buy according to analysts. On December 10, TD Cowen analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. TD Cowen believes that Orchestra BioMed is at the leading edge of cardiovascular device innovation. Its […]
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...